Nanomedicine for Cancer.
Author | Younis, Nour K |
Author | Yassine, Hadi M |
Author | Eid, Ali H |
Available date | 2023-01-29T06:52:25Z |
Publication Date | 2022-12-28 |
Publication Name | Current Medicinal Chemistry |
Identifier | http://dx.doi.org/10.2174/0929867330666221228121947 |
Citation | Younis K Nour, Yassine M. Hadi and Eid H Ali*, Nanomedicine for Cancer, Current Medicinal Chemistry 2023; 30() . https://dx.doi.org/10.2174/0929867330666221228121947 |
ISSN | 0929-8673 |
Abstract | Over the past decades, oncology has occupied the lion’s share of all nanomedical applications [1-3]. In 2020, up to 65% of the clinical trials involving nanomaterials were attending to cancer therapeutics and diagnostics [4]. The focus of most trials is not limited to enhancing the efficacy of available therapeutics or the accuracy and precision of existing diagnostic tools but rather directed to improving the quality of life of cancer patients. Indeed, one approach to overcoming drug resistance can be achieved via modulating the pharmacological characteristics of these therapies [4, 5]. This, in turn, permits their passive and selective delivery to the targeted tumorigenic sites. Furthermore, the use of biocompatible drug delivery systems embracing cancer-specific antibodies facilitates the active delivery of these therapeutics to cancer cells [6]. |
Language | en |
Publisher | Bentham Science Publishers |
Subject | Nanomedicine Cancer |
Type | Other |
Volume Number | 30 |
ESSN | 1875-533X |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [738 items ]
-
Medicine Research [1470 items ]